ABIONYX Pharma 미래 성장

Future 기준 확인 2/6

ABIONYX Pharma 의 수익은 연간 23.4% 감소할 것으로 예상되는 반면, 연간 수익은 40.7% 로 증가할 것으로 예상됩니다. 40.7% 연간. EPS는 연간 13.8% 만큼 쇠퇴할 것으로 예상됩니다.

주요 정보

-23.4%

수익 성장률

-13.8%

EPS 성장률

Biotechs 수익 성장	42.4%
매출 성장률	40.7%
향후 자기자본 수익률	n/a
애널리스트 커버리지	Low
마지막 업데이트	15 Nov 2024

최근 미래 성장 업데이트

업데이트 없음

Recent updates

수익 및 매출 성장 예측

DB:609 - 애널리스트의 미래 추정치 및 과거 재무 데이터 (EUR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	12	-7	-7	-7	1
12/31/2025	7	-9	-9	-9	1
12/31/2024	5	-6	-6	-6	1
6/30/2024	5	-3	-3	-3	N/A
3/31/2024	5	-3	-3	-3	N/A
12/31/2023	5	-4	-4	-4	N/A
9/30/2023	5	-4	N/A	N/A	N/A
6/30/2023	5	-4	-2	-2	N/A
3/31/2023	5	-4	-3	-3	N/A
12/31/2022	5	-4	-4	-3	N/A
9/30/2022	4	-5	N/A	N/A	N/A
6/30/2022	3	-6	-6	-6	N/A
3/31/2022	2	-6	-6	-6	N/A
12/31/2021	1	-6	-7	-7	N/A
9/30/2021	0	-5	N/A	N/A	N/A
6/30/2021	0	-4	-6	-5	N/A
3/31/2021	0	-3	-3	-3	N/A
12/31/2020	N/A	-2	-1	-1	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	0	0	N/A
3/31/2020	N/A	0	-2	-2	N/A
12/31/2019	N/A	2	-4	-4	N/A
9/30/2019	0	1	-5	-5	N/A
6/30/2019	0	0	-6	-6	N/A
3/31/2019	0	-3	-6	-6	N/A
12/31/2018	0	-6	-6	-6	N/A
9/30/2018	0	-7	-6	-6	N/A
6/30/2018	N/A	-8	-7	-7	N/A
3/31/2018	N/A	-6	N/A	-8	N/A
12/31/2017	N/A	-5	N/A	-9	N/A
9/30/2017	N/A	-8	N/A	-11	N/A
6/30/2017	N/A	-11	N/A	-13	N/A
3/31/2017	N/A	-18	N/A	-16	N/A
12/31/2016	N/A	-25	N/A	-19	N/A
9/30/2016	N/A	-25	N/A	-19	N/A
6/30/2016	N/A	-24	N/A	-19	N/A
3/31/2016	N/A	-20	N/A	-16	N/A
12/31/2015	N/A	-17	N/A	-14	N/A
9/30/2015	N/A	-13	N/A	-11	N/A
6/30/2015	N/A	-10	N/A	-8	N/A
3/31/2015	N/A	-8	N/A	-6	N/A
12/31/2014	N/A	-7	N/A	-3	N/A

애널리스트 미래 성장 예측

수입 대 저축률: 609 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 vs 시장: 609 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

고성장 수익: 609 향후 3년 동안 수익성이 없을 것으로 예상됩니다.

수익 대 시장: 609 의 수익(연간 40.7% ) German 시장( 5.6% 보다 빠르게 성장할 것으로 예상됩니다. 5.6% 연간).

고성장 수익: 609 의 수익(연간 40.7% )은 연간 20% 보다 빠르게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: 609 의 자기자본수익률이 3년 내에 높을 것으로 예상되는지 판단하기에는 데이터가 부족합니다.

ABIONYX Pharma 미래 성장

Future 기준 확인 2/6

주요 정보

최근 미래 성장 업데이트

Recent updates

ABIONYX Pharma RACERS Study Clinical Results in Brain-Fog Selected for Poster Presentation at the American Society of Nephrology (ASN) 2024 Annual Meeting Kidney Week

New minor risk - Share price stability

First half 2024 earnings released

ABIONYX Pharma Completes Pre-IND Meeting with the FDA for CER-001 Phase 2b/3 Clinical Trial for Patients with Sepsis

ABIONYX Pharma SA, Annual General Meeting, Jun 27, 2024

ABIONYX Pharma SA to Report Q2, 2024 Results on Aug 22, 2024

New minor risk - Revenue size

Full year 2023 earnings released

ABIONYX Pharma SA to Report Q2, 2024 Results on Sep 26, 2024

ABIONYX Pharma SA Acknowledges the Clinical Results of the Phase 3 Aegis-Ii Study Evaluating the Efficacy and Safety of Csl Behring’S Human-Plasma-Derived Apoa-I, CSL112

ABIONYX Pharma Appoints Rob Scott as Chief Medical Officer and Head of R&D

ABIONYX Pharma Presents Preclinical Results for CER-001 in Brain Fog, At the 1st International Scientific Congress on Brain-Kidney Interaction in Naples on November 23-24, 2023

ABIONYX Pharma Announces New Positive Results in a Uveitis Model for the Strategic Development of the First Class of Biomedicines in Ophthalmology Based on its Recombinant apoA-I

Abionyx Pharma Racers Study Data in Sepsis Presented At the American Society of Nephrology (Asn) 2023 Annual Meeting "Kidney Week"

ABIONYX Pharma RACERS Study in Sepsis Selected for Late-Breaking Clinical Results Poster Presentation at the American Society of Nephrology 2023 Annual Meeting " Kidney Week"

First half 2023 earnings released

ABIONYX Pharma Successfully Manufactures a Second Batch of Recombinant Human ApoA-I CER-001 Using a New, Innovative and Robust Industrial Bioprocess

New major risk - Revenue and earnings growth

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma Announces New Compassionate Access Authorization (CAA) for CER-001 in the Rare Disease LCAT Deficiency or Norum Disease in Europe

ABIONYX Pharma SA, Annual General Meeting, Jun 28, 2023

ABIONYX Pharma SA to Report Q2, 2023 Results on Aug 17, 2023

ABIONYX Pharma Announces Successful Manufacturing of the First Batch of CER-001 with Recombinant Human ApoA-I Using aNew Innovative and Robust Industrial Bioprocess

Full year 2022 earnings released

ABIONYX Pharma Reports Positive Results from Phase 2A Pilot Clinical Trial

ABIONYX Pharma SA to Report Fiscal Year 2022 Results on Apr 27, 2023

Insufficient new directors

Insufficient new directors

ABIONYX Pharma SA Announces Final Patient Enrollment in Phase 2a Clinical Trial with CER-001, Bio-HDL for the Treatment of Patients with Sepsis at High Risk of Developing Acute Kidney Injury

Insufficient new directors

First half 2022 earnings released

ABIONYX Pharma Reports Positive Interim Results from Phase 2A Clinical Trial Evaluating CER-001 in the Treatment of Septic Patients At High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Receives FDA Orphan Drug Designation (ODD) for CER-001 for the Treatment of LCAT Deficiency Presenting as Kidney Dysfunction and/or Ophthalmologic Disease

ABIONYX Pharma SA to Report First Half, 2022 Results on Sep 29, 2022

ABIONYX Pharma Announces That the French Drug Safety Agency Has Granted a Compassionate Access Authorization for the bio-HDL (CER-001) in COVID-19 Disease

ABIONYX Announces First Patient Enrolled in Phase 2a Clinical Study With CER-001, the Bio-HDL for the Treatment of Septic Patients at High Risk of Developing Acute Kidney Injury

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

New 90-day low: €0.83

ABIONYX Announces Positive Clinical Results From CER-001 in an Ultrarare Kidney Disease Published in the Annals of Internal Medicine

ABIONYX Pharma SA to Report First Half, 2021 Results on Sep 09, 2021

New 90-day high: €1.04

ABIONYX Pharma SA Initiates a Phase 2a Clinical Trial With CER-001 in Septic Patients at High Risk of Developing Acute Kidney Injury

ABIONYX Pharma Announces Publication of Pre-Clinical Data in the Journal Metabolism Demonstrating CER-001 Improves Lipid Profile and Kidney Function for an Ultra-Rare Kidney Disease

New 90-day high: €1.04

ABIONYX Pharma Announces the Observation of Positive Therapeutic Signals in Temporary Authorizations for Use (ATUn) in France and Italy for an Ultra-Rare Kidney Disease

New 90-day low: €0.71

ABIONYX Pharma SA announced that it expects to receive €1.859997 million in funding from Domundi SC and other investors

New 90-day low - €0.74

수익 및 매출 성장 예측

애널리스트 미래 성장 예측

주당 순이익 성장 예측

미래 자기자본 수익률

성장 기업 발견